356 related articles for article (PubMed ID: 18282481)
1. The Sirtuin family: therapeutic targets to treat diseases of aging.
Milne JC; Denu JM
Curr Opin Chem Biol; 2008 Feb; 12(1):11-7. PubMed ID: 18282481
[TBL] [Abstract][Full Text] [Related]
2. Study of 1,4-dihydropyridine structural scaffold: discovery of novel sirtuin activators and inhibitors.
Mai A; Valente S; Meade S; Carafa V; Tardugno M; Nebbioso A; Galmozzi A; Mitro N; De Fabiani E; Altucci L; Kazantsev A
J Med Chem; 2009 Sep; 52(17):5496-504. PubMed ID: 19663498
[TBL] [Abstract][Full Text] [Related]
3. SIRTUIN 1: regulating the regulator.
Zschoernig B; Mahlknecht U
Biochem Biophys Res Commun; 2008 Nov; 376(2):251-5. PubMed ID: 18774777
[TBL] [Abstract][Full Text] [Related]
4. Sirtuins--novel therapeutic targets to treat age-associated diseases.
Lavu S; Boss O; Elliott PJ; Lambert PD
Nat Rev Drug Discov; 2008 Oct; 7(10):841-53. PubMed ID: 18827827
[TBL] [Abstract][Full Text] [Related]
5. Sirtuin inhibitors.
Alcaín FJ; Villalba JM
Expert Opin Ther Pat; 2009 Mar; 19(3):283-94. PubMed ID: 19441904
[TBL] [Abstract][Full Text] [Related]
6. After the grape rush: sirtuins as epigenetic drug targets in neurodegenerative disorders.
Huber K; Superti-Furga G
Bioorg Med Chem; 2011 Jun; 19(12):3616-24. PubMed ID: 21306906
[TBL] [Abstract][Full Text] [Related]
7. Small molecule regulation of Sir2 protein deacetylases.
Grubisha O; Smith BC; Denu JM
FEBS J; 2005 Sep; 272(18):4607-16. PubMed ID: 16156783
[TBL] [Abstract][Full Text] [Related]
8. Identification of a small molecule SIRT2 inhibitor with selective tumor cytotoxicity.
Zhang Y; Au Q; Zhang M; Barber JR; Ng SC; Zhang B
Biochem Biophys Res Commun; 2009 Sep; 386(4):729-33. PubMed ID: 19559674
[TBL] [Abstract][Full Text] [Related]
9. Structure-activity studies on suramin analogues as inhibitors of NAD+-dependent histone deacetylases (sirtuins).
Trapp J; Meier R; Hongwiset D; Kassack MU; Sippl W; Jung M
ChemMedChem; 2007 Oct; 2(10):1419-31. PubMed ID: 17628866
[TBL] [Abstract][Full Text] [Related]
10. Oxadiazole-carbonylaminothioureas as SIRT1 and SIRT2 inhibitors.
Huhtiniemi T; Suuronen T; Rinne VM; Wittekindt C; Lahtela-Kakkonen M; Jarho E; Wallén EA; Salminen A; Poso A; Leppänen J
J Med Chem; 2008 Aug; 51(15):4377-80. PubMed ID: 18642893
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic potential of sirtuin-activating compounds in Alzheimer's disease.
Gan L
Drug News Perspect; 2007 May; 20(4):233-9. PubMed ID: 17637936
[TBL] [Abstract][Full Text] [Related]
12. Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease.
Outeiro TF; Kontopoulos E; Altmann SM; Kufareva I; Strathearn KE; Amore AM; Volk CB; Maxwell MM; Rochet JC; McLean PJ; Young AB; Abagyan R; Feany MB; Hyman BT; Kazantsev AG
Science; 2007 Jul; 317(5837):516-9. PubMed ID: 17588900
[TBL] [Abstract][Full Text] [Related]
13. Sirtuin modulators: an updated patent review (2012 - 2014).
Mellini P; Valente S; Mai A
Expert Opin Ther Pat; 2015 Jan; 25(1):5-15. PubMed ID: 25435179
[TBL] [Abstract][Full Text] [Related]
14. Thiobarbiturates as sirtuin inhibitors: virtual screening, free-energy calculations, and biological testing.
Uciechowska U; Schemies J; Neugebauer RC; Huda EM; Schmitt ML; Meier R; Verdin E; Jung M; Sippl W
ChemMedChem; 2008 Dec; 3(12):1965-76. PubMed ID: 18985648
[TBL] [Abstract][Full Text] [Related]
15. Structural basis of inhibition of the human NAD+-dependent deacetylase SIRT5 by suramin.
Schuetz A; Min J; Antoshenko T; Wang CL; Allali-Hassani A; Dong A; Loppnau P; Vedadi M; Bochkarev A; Sternglanz R; Plotnikov AN
Structure; 2007 Mar; 15(3):377-89. PubMed ID: 17355872
[TBL] [Abstract][Full Text] [Related]
16. Identification and characterization of proteins interacting with SIRT1 and SIRT3: implications in the anti-aging and metabolic effects of sirtuins.
Law IK; Liu L; Xu A; Lam KS; Vanhoutte PM; Che CM; Leung PT; Wang Y
Proteomics; 2009 May; 9(9):2444-56. PubMed ID: 19343720
[TBL] [Abstract][Full Text] [Related]
17. A therapeutic role for sirtuins in diseases of aging?
Westphal CH; Dipp MA; Guarente L
Trends Biochem Sci; 2007 Dec; 32(12):555-60. PubMed ID: 17980602
[TBL] [Abstract][Full Text] [Related]
18. Linking SIRT2 to Parkinson's disease.
Garske AL; Smith BC; Denu JM
ACS Chem Biol; 2007 Aug; 2(8):529-32. PubMed ID: 17708669
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic potential of activators and inhibitors of sirtuins.
Balcerczyk A; Pirola L
Biofactors; 2010; 36(5):383-93. PubMed ID: 20848588
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of human sirtuins by in situ generation of an acetylated lysine-ADP-ribose conjugate.
Asaba T; Suzuki T; Ueda R; Tsumoto H; Nakagawa H; Miyata N
J Am Chem Soc; 2009 May; 131(20):6989-96. PubMed ID: 19413317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
